Holly L. Peay - Concepedia

Author

Holly L. Peay

Also Known As

Asbjørg Stray-Pedersen, Crissman, Blythe G., George Padberg, H Peay, H. L. Peay, H. Peay, H.L. Peay, Holly L. Peay, Holly L Peay, Holly L. Peay

213

Publications

4.1K

Citations

H-Index

146

Concepts

All Affiliations

RTI International Parent Project Muscular Dystrophy University of North Carolina at Chapel Hill National Human Genome Research Institute Johns Hopkins University

About

Holly L. Peay is an author at RTI International specializing in medicine, rehabilitation, and pediatrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	6	6	211
2	Education	5	5	93
3	Business	2	2	31
4	Engineering	1	1	717
5	Management	1	1	10

Holly L. Peay

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations Catherine L. Bladen, David Salgado, Soledad Monges, Human Mutation Dmd MutationsTrial PlanningEngineeringMendelian DisorderGenetic Disorder	2015	717
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting Boris Jülg, Lynda Dee, Jintanat Ananworanich, The Lancet HIV Treatment And PreventionConsensus MeetingClinical TrialsHiv Research Trials—reportAntiviral Therapy	2019	198
Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database Zaïda Koeks, Catherine L. Bladen, David Salgado, Journal of Neuromuscular Diseases	2017	171
Reporting Formative Qualitative Research to Support the Development of Quantitative Preference Study Protocols and Corresponding Survey Instruments: Guidelines for Authors and Reviewers Ilene L. Hollin, Benjamin M. Craig, Joanna Coast, Patient Formative Qualitative ResearchSurvey (Human Research)Health PolicyQualitative AnalysisConsumer Research	2019	169
A Community-Engaged Approach to Quantifying Caregiver Preferences for the Benefits and Risks of Emerging Therapies for Duchenne Muscular Dystrophy Holly L. Peay, Ilene L. Hollin, Ryan Fischer, Clinical Therapeutics	2014	111
Practical Considerations in Using Online Modified-Delphi Approaches to Engage Patients and Other Stakeholders in Clinical Practice Guideline Development Dmitry Khodyakov, Sean Grant, Brian Denger, Patient	2019	106
The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia Catherine L. Bladen, Karen Rafferty, Volker Straub, Human Mutation Rare DiseasesDmd RegistriesDuchenne Muscular DystrophyPrecision MedicineClinical Trials	2013	103
Defining personal utility in genomics: A Delphi study Jennefer N. Kohler, Erin Turbitt, Katie L. Lewis, Clinical Genetics	2017	95
<i>DMD</i> genotype correlations from the Duchenne Registry: Endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype Richard T. Wang, Florian Barthélémy, Ann Martin, Human Mutation GeneticsGenetic EpidemiologyMolecular BiologyDisease Gene IdentificationDefined Mutation Subtype	2018	81
Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment Gail E. Henderson, Holly L. Peay, Eugène Kroon, Journal of Medical Ethics	2017	69

Page 1